中国神经再生研究(英文版) ›› 2024, Vol. 19 ›› Issue (6): 1183-1184.doi: 10.4103/1673-5374.385861

• 观点:退行性病与再生 • 上一篇    下一篇

代谢产物和微营养素在调节肌萎缩侧索硬化中的作用

  

  • 出版日期:2024-06-15 发布日期:2023-11-17

Metabolites and micronutrition in modulating amyotrophic lateral sclerosis

Katerina Claud, Jun Sun*   

  1. Department of Medicine, University of Illinois Chicago, Chicago, IL, USA (Claud K, Sun J)
    Jesse Brown VA Medical Center Chicago, Chicago, IL, USA (Sun J)
  • Online:2024-06-15 Published:2023-11-17
  • Contact: Jun Sun, PhD, junsun7@uic.edu.
  • Supported by:
    This work was supported by VA Merit Award 1 I01 BX004824-01, National Institute of Diabetes and Digestive and Kidney Diseases (R01DK105118-01 and R01DK114126); and United States Department of Defense Congressionally Directed Medical Research Programs (BC191198) (all to JS). The contents do not represent the views of the United States Department of Veterans Affairs or the United States Government. The study sponsor plays no role in the study design in the collection, analysis, and interpretation of data. Katerina Claud was a summer high school student at UIC and currently is an undergraduate at Northwestern University.

摘要: https://orcid.org/0000-0001-7465-3133 (Jun Sun)

Abstract: Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease. The majority of ALS cases are sporadic with only about 20% of familial forms. Even in families with genetic predisposition, there is significant phenotypic variability, suggesting that ALS onset may be triggered by a combination of genetic factors, environmental factors (e.g., military service, deployments, exposures) (Beard and Kamel, 2015), lifestyle changes (e.g., cigarette smoke and dietary), and gut microbiome alteration. From our 2017 research paper demonstrating the beneficial role of the microbial metabolite butyrate (Zhang et al., 2017) to the newly approved Food and Drug Administration drug Relyvrio on September 29, 2022, the novel concepts and role of the gut microbiome and microbial metabolites in ALS pathogenesis have been slowly recognized by the neurology research field. Relyvrio is a combination of two drugs, sodium phenylbutyrate, and taurursodiol, that has been shown to reduce the rate of decline on a clinical assessment of daily functioning and is associated with longer overall survival (Paganoni et al., 2020). However, the role of sodium phenylbutyrate on intestinal function and microbiome in ALS progression was not included in the study, and research on metabolites correlated with the gut microbiome in ALS progression and treatment is still limited. A better understanding of the dynamic interactions among microbial metabolites, neuroactive metabolites, and inflammation in ALS will provide innovative insights into ALS prevention and treatment.